title: Novel and Effective Almagate Enema for Hemorrhagic Chronic Radiation Proctitis and Risk Factors for Fistula Development.
abstract: Radiation proctitis is a common complication after radiotherapy for pelvic malignant tumors. This study was conducted to assess the efficacy of novel almagate enemas in hemorrhagic chronic radiation proctitis (CRP) and evaluate risk factors related to rectal deep ulcer or fistula secondary to CRP. All patients underwent a colonoscopy to confirm the diagnosis of CRP and symptoms were graded. Typical endoscopic and pathological images, risk factors, and quality of life were also recorded. A total of 59 patients were enrolled. Gynecological cancers composed 93.1% of the primary malignancies. Complete or obvious reduction of bleeding was observed in 90% (53/59) patients after almagate enema. The mean score of bleeding improved from 2.17 to 0.83 (P<0.001) after the enemas. The mean response time was 12 days. No adverse effects were found. Moreover, long-term successful rate in controlling bleeding was 69% and the quality of life was dramatically improved (P=0.001). The efficacy was equivalent to rectal sucralfate, but the almagate with its antacid properties acted more rapidly than sucralfate. Furthermore, we firstly found that moderate to severe anemia was the risk factor of CRP patients who developed rectal deep ulcer or fistulas (P= 0.015). We also found abnormal hyaline-like thick wall vessels, which revealed endarteritis obliterans and the fibrosis underlying this disease. These findings indicate that almagate enema is a novel effective, rapid and well-tolerated method for hemorrhagic CRP. Moderate to severe anemia is a risk factor for deep ulceration or fistula.
authors.affiliation: Department of Colorectal Surgery, the Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China E-mail : leiwangyinhu@126.com, wangl9@mail. sysu.edu.cn, wjp@mail.sysu.edu.cn.
authors.forename: Zi-Xu
authors.initials: ZX
authors.lastname: Yuan
authors.forename: Teng-Hui
authors.initials: TH
authors.lastname: Ma
authors.forename: Qing-Hua
authors.initials: QH
authors.lastname: Zhong
authors.forename: Huai-Ming
authors.initials: HM
authors.lastname: Wang
authors.forename: Xi-Hu
authors.initials: XH
authors.lastname: Yu
authors.forename: Qi-Yuan
authors.initials: QY
authors.lastname: Qin
authors.forename: Li-Li
authors.initials: LL
authors.lastname: Chu
authors.forename: Lei
authors.initials: L
authors.lastname: Wang
authors.forename: Jian-Ping
authors.initials: JP
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D000536:Aluminum Hydroxide / Q000627:therapeutic use*; D000863:Antacids / Q000627:therapeutic use; D002254:Carbonates / Q000627:therapeutic use*; D003113:Colonoscopy; D004733:Enema / Q000379:methods*; D005260:Female; D005402:Fistula / Q000175:diagnosis / Q000209:etiology*; D005500:Follow-Up Studies; D006471:Gastrointestinal Hemorrhage / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D006801:Humans; D008276:Magnesium Hydroxide / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009369:Neoplasms / Q000150:complications* / Q000473:pathology / Q000532:radiotherapy; D011349:Proctitis / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D011379:Prognosis; D011788:Quality of Life; D011832:Radiation Injuries / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D011878:Radiotherapy / Q000009:adverse effects*; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D000863:Antacids; D002254:Carbonates; C043698:almagate; D000536:Aluminum Hydroxide; D008276:Magnesium Hydroxide